Preclinical Assessment of the PI3Kα Selective Inhibitor Inavolisib and Prediction of Its Pharmacokinetics and Efficacious Dose in Human

Authors: Salphati L, Pang J, Plise EG, Cheong J, Braun MG, Friedman LS, Hong Thibodeau R, Jaochico A, Johnson R, Liu N, Nannini M, Sampath D, Song K, Hannan EJ, Staben ST
Publication: Xenobiotica
Keywords: dose optimization, dose selection, fih, first-in-human, gastroplus, PBPK modeling, physiologically based pharmacokinetics, translational science
Software: GastroPlus®
Division: PBPK

Abstract

1. Small molecule inhibitors of the PI3K pathway have been extensively investigated as potential anticancer agents. Among the effectors in this pathway, PI3Kα is the kinase most frequently associated with the development of tumors, through mutations and amplifications of the PIK3CA gene encoding the p110α catalytic subunit.

2. Inavolisib (GDC-0077) is a potent and PI3Kα-selective inhibitor that also specifically triggers the degradation of the mutant p110α protein.

3. We characterized inavolisib ADME properties in preclinical in vitro and in vivo studies, assessed its efficacy in the PIK3CA mutant KPL-4 breast cancer xenograft model, and predicted its pharmacokinetics and efficacious dose in humans.

4. Inavolisib had a moderate permeability (1.9•10−6 cm/s) in MDCK cells and was a P-gp and Bcrp1 substrate. It appeared metabolically stable in hepatocytes incubations from human and preclinical species. The systemic clearance was low in mouse, monkey and dog and high in rat. Oral bioavailability ranged from 57.5% to 100%. Inavolisib was efficacious in the KPL-4 sub-cutaneous xenograft model.

5. The PK/PD model parameters estimated from the efficacy study, combined with PBPK model-predicted human PK profiles, projected that a dose of 3 mg could lead to clinical response. Inavolisib is currently being tested in phase 3 trials.

By Laurent Salphati, Jodie Pang, Emile G. Plise, Jonathan Cheong, Marie-Gabrielle Braun, Lori S. Friedman, Rebecca Hong Thibodeau, Allan Jaochico, Ryan Johnson, Ning Liu, Michelle Nannini, Deepak Sampath, Kyung Song, Emily J. Hannan & Steven T. Staben